Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung Cancer

AstraZeneca recently announced that the U.S. FDA has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) in combination with chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The decision is based on FLAURA2 Phase III trial results which extended median progression-free survival by nearly 9 months versus standard of care. Each year, there are an estimated 2.2 million people diagnosed with lung cancer globally with 80-85% of patients diagnosed with NSCLC, the most common form of lung cancer. Approximately 70% of people are diagnosed with advanced NSCLC. TAGRISSO is a step closer to providing additional options that could offer significant improvements for this patient population. Lung Cancers Today spoke with Arun Krishna, VP, Head of US Lung Cancer Franchise at AstraZeneca, about what the findings of FLAURA2 mean for patients with advanced lung cancer. #LCAM #LungCancer #TAGRISSO #nsclc